60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study

Thromb Res. 2020 Jun:190:60-61. doi: 10.1016/j.thromres.2020.03.014. Epub 2020 Mar 19.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome* / drug therapy
  • China
  • Clopidogrel / therapeutic use
  • Cross-Over Studies
  • Humans
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Function Tests
  • Single-Blind Method
  • Ticagrelor / therapeutic use
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticagrelor